Group 1 - Moretus Research provides high-quality equity research focused on U.S. public markets, aiming to deliver clarity, conviction, and alpha for serious investors [1] - The research framework identifies companies with durable business models, mispriced cash flow potential, and intelligent capital allocation, emphasizing a structured and repeatable approach [1] - Valuation methods are based on sector-relevant multiples tailored to each company's business model and capital structure, prioritizing comparability, simplicity, and relevance [1] Group 2 - Research coverage focuses on underappreciated companies experiencing structural changes or temporary dislocations, where disciplined analysis can yield asymmetric returns [1] - Moretus Research aims to elevate the standard for independent investment research by providing professional-grade insights and actionable valuation [1]

Core Insights - AbbVie is experiencing stability in price action and offers attractive dividend yields, but there are underlying issues in the investment thesis beyond the aging Humira patent cliff [1] Group 1: Company Analysis - AbbVie is facing challenges related to the expiration of the Humira patent, which is a significant concern for its future revenue streams [1] - The company has a strong focus on equity valuation, market trends, and portfolio optimization to identify high-growth investment opportunities [1] Group 2: Analyst Background - The analysis is conducted by a seasoned analyst with over 20 years of experience in quantitative research, financial modeling, and risk management, emphasizing a long-term perspective on value creation [1] - The analyst has previously held a Vice President position at Barclays, leading teams in model validation and stress testing, showcasing a deep expertise in both fundamental and technical analysis [1]

Core Insights - Insmed Inc experienced a significant stock surge of 45% in the last month, driven by successful Phase IIb trial results for its inhalation therapy TPIP in pulmonary arterial hypertension (PAH) [2] - The company is currently trading at a high valuation of 35 times sales, which translates to a low sales yield of 2.8%, raising concerns about its sustainability [3] - Insmed's stock premium is primarily attributed to the positive trial results and a $750 million capital raise aimed at pipeline expansion, leading to investor optimism [4][5] Financial Performance - Insmed projects global revenues for its product ARIKAYCE to be between $405 million and $425 million in 2025, indicating an 11-17% growth compared to 2024 [6] - The company is expected to remain unprofitable into 2026 due to ongoing investments in research and development for pipeline products [6] Future Outlook - The FDA's decision on brensocatib in August and the initiation of Phase 3 trials for TPIP are critical upcoming milestones that could significantly impact Insmed's stock performance [7] - Successful execution of Phase 3 trials and commercial launches of both brensocatib and TPIP will be essential for maintaining the current premium valuation [7][8]

Group 1 - Carlyle Secured Lending (CGBD) reported Q1 results with a dividend yield of 11.5% and a 16% discount to NAV [1] - The net investment income price yield for CGBD is 11.8%, which aligns with market expectations [1]

作者：MD 出品：明亮公司 近日，知名投资播客 Inv est Like the Best 再次邀请到 Be nchmark 的合伙人 Bill Gurley，全面 讨论 了当下美国一级市场的现实问题，以及 AI企业目前的估值和投资矛盾。 在访谈中， Bill剖析了当前风险投资行业的结构性变化与挑战。 他指出，MegaFund的崛起使得资金 规模成倍增长， 早期和后期投资界限模糊， 巨额资本推动了大量 AI和科技独角兽的诞生。然而， 这些公司中存在大量"僵尸独角兽"，即融资巨大但增长乏力、真实价值存疑的企业。 Bill强调，当前 市场中，无论是GP、LP还是创始人 ，可能 缺乏准确标记资产和主动修正估值的动力， 导致账面价 值与实际价值严重背离，激励机制错位。 在访谈中， Bill 还分析了零利率环境下的投资（投机）环境，资本过剩延长了公司 "存活期"，使得 本应被市场淘汰的企业依然存在，市场竞争格局变得异常复杂。与此同时，IPO和并购窗口的关闭让 大量资本被 困 在一级市场 ， LP的流动性问题日益突出， 甚至名校捐赠基金也不得不通过发债或抛 售私募资产来应对资金压力。 Bill 还 认为， AI浪潮的到来 ...

Core Viewpoint - The comparison between Carnival (CCL) and Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) indicates that CCL currently offers better value for investors based on various financial metrics and rankings [1][3][7]. Valuation Metrics - CCL has a forward P/E ratio of 12.63, while ATAT has a forward P/E of 20.03, suggesting that CCL is more attractively priced [5]. - The PEG ratio for CCL is 0.55, compared to ATAT's PEG ratio of 0.92, indicating that CCL may offer better value relative to its expected earnings growth [5]. - CCL's P/B ratio stands at 2.99, significantly lower than ATAT's P/B ratio of 9.91, further supporting the notion that CCL is undervalued [6]. Zacks Rank and Value Grades - CCL holds a Zacks Rank of 2 (Buy), while ATAT has a Zacks Rank of 3 (Hold), indicating a stronger earnings outlook for CCL [3][7]. - CCL has a Value grade of A, whereas ATAT has a Value grade of C, reflecting CCL's superior valuation metrics [6].

MicroStrategy (MSTR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this business software company have returned -4.4%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Computer - Software industry, which MicroStrategy falls in, has gained 6.9%. The key question now is: What could be the stock's f ...

Agnico Eagle Mines (AEM) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this gold mining company have returned +14.6%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Mining - Gold industry, which Agnico falls in, has gained 13%. The key question now is: What could be the stock's future direction?Although media repor ...

Core Viewpoint - Boeing's stock is currently viewed as unattractive due to poor operational performance and financial health, despite a seemingly reasonable valuation of approximately $205 [3][13]. Financial Performance - Boeing's revenues have declined by 9.2% from $76 billion to $69 billion in the past 12 months, contrasting with a 5.5% growth for the S&P 500 [11] - The company's operating income over the last four quarters was -$10 billion, resulting in an operating margin of -14.7%, compared to 13.2% for the S&P 500 [11] - Boeing's net income for the last four quarters was -$12 billion, leading to a net income margin of -16.6%, while the S&P 500 had a margin of 11.6% [11] Valuation Metrics - Boeing has a price-to-sales (P/S) ratio of 2.3, which is lower than the S&P 500's ratio of 3.0 [5]. - The stock has fallen 57.0% from a high of $269.19 on March 12, 2021, to $115.86 on June 13, 2022, compared to a peak-to-trough decline of 25.4% for the S&P 500 [12]. Growth and Profitability - Boeing's top line has increased at an average rate of 4.9% over the last three years, compared to a 5.5% rise for the S&P 500 [11]. - Boeing's profit margins are significantly lower than most companies in the Trefis coverage universe, indicating extremely weak profitability [7][15]. Financial Stability - Boeing's total debt was $54 billion at the end of the most recent quarter, with a market capitalization of $154 billion, resulting in a high debt-to-equity ratio of 32.9% compared to 19.9% for the S&P 500 [11]. - Cash and cash equivalents account for $24 billion of Boeing's total assets of $156 billion, leading to a moderate cash-to-assets ratio of 15.1% [11]. Downturn Resilience - Boeing's stock has performed significantly worse than the S&P 500 during recent downturns, indicating extremely weak resilience [9][15]. - The stock has not yet recovered to its pre-crisis peak, highlighting ongoing challenges [12].

Core Viewpoint - Qualcomm's stock has shown moderate performance with a year-to-date increase of approximately 3% amid U.S.-China trade uncertainties, but the company reported strong Q2 FY'25 results, with revenue up 15% year-over-year to $10.84 billion and earnings per share at $2.85, driven by a rebound in the smartphone market [2][3] Revenue Growth - Qualcomm's revenue has grown at an average rate of 5.3% over the past three years, slightly below the S&P 500's 5.5% growth [5] - In the last 12 months, Qualcomm's revenue increased by 12.1%, from $36 billion to $42 billion, compared to the S&P 500's 5.5% growth [5] - Quarterly revenues rose by 17.5% to $11 billion from $9.4 billion a year prior, outperforming the S&P 500's 4.8% improvement [5] Profitability Metrics - Qualcomm has a price-to-sales (P/S) ratio of 4.2, compared to 3.0 for the S&P 500 [7] - The company's price-to-free cash flow (P/FCF) ratio is 12.4, while the S&P 500 stands at 20.5 [7] - Qualcomm's price-to-earnings (P/E) ratio is 16.2, significantly lower than the S&P 500's 26.4 [7] - The operating margin for Qualcomm is 26.4%, compared to 13.2% for the S&P 500, indicating strong profitability [8] Financial Stability - Qualcomm's debt is $15 billion, with a market capitalization of $176 billion, resulting in a debt-to-equity ratio of 8.5%, lower than the S&P 500's 19.9% [10] - Cash and cash equivalents amount to $14 billion out of $55 billion in total assets, leading to a cash-to-assets ratio of 25.7%, compared to 13.8% for the S&P 500 [10] Downturn Resilience - Qualcomm's stock has shown slightly better performance than the S&P 500 during recent downturns, including a 45.1% decline during the inflation shock of 2022, compared to a 25.4% decline for the S&P 500 [12] - The stock fully recovered to its pre-crisis peak by May 2024 and has since risen to around $160 [12] - Historical performance during the COVID-19 pandemic and the global financial crisis also indicates resilience, with Qualcomm recovering fully from significant declines [12][13] Overall Assessment - Qualcomm's operational performance and financial standing are assessed as very strong across key metrics, making the stock appealing at its current valuation [3][15]